BLOG

Interim Clinical Data Give Hopes for Waldenström’s Macroglobulinemia Patients

Paula Ragan, PhD, CEO and President, X4 Pharmaceuticals, discusses positive interim data from the phase 1b clinical trial (NCT04274738) evaluating mavorixafor in combination with ibrutinib in double-mutation Waldenström’s Macroglobulinemia (WM) patients.